APP下载

雷珠单抗注射液治疗眼底病的临床疗效

2021-10-30刘建慧

康颐 2021年17期
关键词:临床疗效

刘建慧

【摘要】目的:评价分析雷珠单抗注射液治疗眼底病的临床疗效。方法:选取昌邑市人民医院2020年3月至2021年2月诊治的眼底病病患共84例作为研究对象,并且按随机数字方法分为两组参照组和实验组,每组眼底病病患各42例作为研究对象,参照组予以曲安奈德注射液治疗,实验组予以雷珠单抗注射液治疗。对比各组治疗前后眼压和视力水平改善情况,以及不良反应情况。结果:经研究各组治疗前眼压和视力水平对比(P>0.05),经治疗后实验组眼压水平较参照组低,视力水平较参照组高;不良反应发生率4.76%较参照组的23.81%低,各组对比(P<0.05)。结论:雷珠单抗注射液治疗眼底病疗效确切,有利于改善病患眼压水平,促进其视力恢复,降低不良反应发生风险,从而提升整体疗效,值得临床广泛应用。

【关键词】雷珠单抗注射液;眼底病;临床疗效

【中图分类号】R773.4 【文献标识码】A 【DOI】

Clinical efficacy of leizhumab injection in the treatment of fundus diseases

LIU Jianhui

(Changyi people’s Hospital  Shandong Changyi 261300)

【Abstract】Objective: To evaluate and analyze the clinical efficacy of leizhumab injection in the treatment of fundus diseases. Methods: a total of 84 patients with fundus diseases diagnosed and treated in Changyi people’s Hospital from March 2020 to February 2021 were selected as the research object, and were randomly divided into two groups: reference group and experimental group. 42 patients in each group were used as the research object. The reference group was treated with triamcinolone acetonide injection and the experimental group was treated with leizumab injection. The improvement of intraocular pressure, visual acuity and adverse reactions were compared before and after treatment. Results: the IOP and visual acuity of each group were compared before treatment (P>0.05). After treatment, the IOP level of the experimental group was lower and the visual acuity level was higher than that of the reference group; The incidence of adverse reactions was 4.76%, which was lower than 23.81% in the reference group (P<0.05). Conclusion: leizhumab injection is effective in the treatment of fundus diseases, which is conducive to improve the level of intraocular pressure, promote the recovery of vision, reduce the risk of adverse reactions, so as to improve the overall curative effect. It is worthy of wide clinical application.

【Key words】leizhumab injection; Fundus disease; Clinical efficacy

眼底病是临床常见病和多发病,发病部位多在视网膜、视盘和脉络膜等,主要是因玻璃體异常而致,对病患视力影响极大,如治疗不及时或不当极易导致失明[1-3]。现今,临床对于眼底病的治疗多采用手术和药物联合治疗,曲安奈德就是较为常用的药物之一,对控制病患眼压水平,改善其视力水平均有着相应的效果,但是其安全性不良太好,易引发恶心、眼痛、头晕和飞蚊症等一系列不良反应[4]。雷珠单抗作为抗新生血管形成类的新型药物,可通过结合血管内皮生长因子来抑制血管的形成及渗透,从而防止脉络膜新生血管的形成[1]。近年来,雷珠单抗已被逐渐应用于临床对于眼底病的治疗中,为进一步证实其疗效,本文开展了此次研究进行评价分析,现报道如下。

1 资料与方法

1.1 一般资料

将2020年3月至2021年2月诊治的眼底病病患84例为研究对象,按随机数字法分为两组各42例,参照组男23例,女19例;年龄24至76岁(53.7±6.2)岁;病程0.5至5年(2.6±1.3)年。实验组男24例,女18例;年龄24至75岁(54.1±6.2)岁;病程0.6至5年(2.4±1.6)年。入选标准:均符合《眼底病诊断与治疗相关诊断标准》内的相关诊断标准[2],均自愿参与研究。剔除标准:对所用药物过敏者;合并恶性肿瘤、脏器疾病、意识障碍和脑血管疾病者。各组普通资料比较(P>0.05),具可比性。

1.2 方法

各组均根据具体病情实施相应的手术治疗,参照组同时予以曲安奈德注射液(厂商:昆明积大制药股份有限公司,批准文号:H53021604)进行玻璃腔体注射治疗,取其25mg注射于患眼颞下方角膜缘后3.5至4.00处,完成注射后拔出针头用湿棉签按压2min左右,待眼压恢复正常后予以抗生素眼膏涂抹,覆盖纱布至隔日。实验组同时予以雷珠单抗注射液(厂商:Novartis PharmaSteinAG,批准文号:S20140003)进行玻璃腔体注射治疗,取其0.5mg注入患眼,注射方法同参照组一致。各组每月均注射治疗一次,治疗3次后比较疗效。

1.3 观察指标

对比各组治疗前后眼压和视力水平改善情况,以及不良反应情况。

1.4 统计学分析

本次研究采用SPSS19.0处理数据,计量资料以(x±s)表示,行t检验,计数资料以(%)表示,行X 2检验,检验标准以P<0.05为有统计学意义。

2 结果

2.1 对比各组治疗前后眼压和视力改善情况

各组治疗前眼压和视力水平对比(P>0.05),经治疗后实验组眼压水平较参照组低,视力水平较参照组高(P<0.05),如表1。

2.2 对比各组不良反应发生情况

实验组不良反应发生率4.76%较参照组的23.81%低(P<0.05),如表2。

3 讨论

眼底病具有病程长、难治愈、易复发等特点,随着病情进展可引发诸多并发病,从而影响病患眼部结构及视功能,进而影响其学习、工作和日常生活,因此及时予以有效的治疗措施具有重要意义[5-7]。

现今,临床治疗眼底病的方法较多,主要有药物对症治疗、激素治疗及激光治疗等,但从既往临床结果发现效果并不理想,不论从总体疗效还是安全性上均有待提升。如学者周美华在研究中就發现,应用曲安奈德注射液治疗眼底病效果并不显著,且易引发诸多不良反应,而用新型抗新生血管形成药雷珠单抗注射液可有效降低不良反应发生风险,改善病患眼压水平,促进其视力恢复[8-10]。本研究结果与之相符,显示经治疗后实验组眼压水平较参照组低,视力水平较参照组高;不良反应发生率4.76%较参照组的23.81%低,各组对比(P<0.05),可见应用雷珠单抗注射液治疗眼底病不仅疗效确切,而且安全性更高。在临床的不断探索下,雷珠单抗近年来已大量应用于眼底病的治疗中,其作为新兴的皮质类固醇激素,属人源化重组单克隆抗体片段,通过注射于玻璃体腔内可有效选择内皮血管细胞生长因子,能快速渗透视网膜,抑制炎症因子释放,降低炎症水平,从而缓解视网膜水肿、出血等临床症状,进而达到控制眼压的目的,最终促进患眼快速康复,提升患眼视力[11-13]。

综上所述,雷珠单抗注射液治疗眼底病疗效确切,有利于改善病患眼压水平,促进其视力恢复,降低不良反应发生风险,从而提升整体疗效,值得临床广泛应用。

参考文献:

[1]侯磊,杨玲,陈婷.评估玻璃体腔注射雷珠单抗对眼底病患者治疗的效果与眼压情况[J].名医,2020(12):265-266.

[2]Xu J F , Yang L J , Mo L , et al. Effective study in the real-world study of intravitreal anti-VEGF drugs injection in the treatment of fundus diseases[J]. International Eye Science,2017,13(11):107-108.

[3]沈文财.玻璃体腔注射雷珠单抗治疗眼底病的临床效果观察[J].临床医药文献电子杂志,2018,5(87):50.

[4]康皞,王彬.玻璃体腔注射雷珠单抗对眼底病患者血流动力学的影响[J].中国医学工程,2017,25(09):29-31.

[5]Xiong-Xiong M A , Wang D Y , Wang L L , et al. Comparative Analysis of Clinical Efficacy of Laser Photocoagulation at Different Wavelengths Combined with Ranibizumab in the Treatment of Non-proliferative Diabetic Retinopathy[J]. Clinical Misdiagnosis & Mistherapy,2019,47(11):1011-1014.

[6] Hao S W . Analysis of Clinical Efficacy of Fundus Laser Combined with Lucentis in the Treatment of Diabetic Retinopathy[J]. Smart Healthcare, 2018, 29(017):3077-3078.

[7]Bu T , Yuhan X U , Liu X , et al.Clinical Efficacy of Entecavir Combined With Kang’ai Injection in the Treatment of Primary Liver Cancer[J].China Continuing Medical Education, 2019 , 015(003):183,185.

[8]汪涛,刘建军,顾永辉.眼底激光联合眼内注射雷珠单抗治疗糖尿病视网膜病变的疗效比较[J].航空航天医学杂志,2018,029(008):964-966.

[9]Li L ,Ophthalmology D O,Hospital D F.Observation on clinical efficacy of Kangbai Xipu injection in the treatment of exudative age-related macular degeneration[J].Chinese Journal of Modern Drug Application, 2019 ,27,(29):152-154+161.

[10]陳宜,冯婧,孟宪芬,etal.玻璃体腔注射雷珠单抗治疗早产儿视网膜病变疗效观察[J].中华眼底病杂志,2015,31(001):6-9.

[11]Li L ,Ophthalmology D O ,Hospital D F .Observation on clinical efficacy of Kangbai Xipu injection in the treatment of exudative age-related macular degeneration[J].Chinese Journal of Modern Drug Application,2019 , 30(3):245-248.

[12]Luo J B , Fan-Zhou H E , Chen H X .Observation on clinical efficacy of Shenqi Fuzheng injection in the treatment of gastrointestinal cancer and cancer-related fatigue of lung cancer[J].China Practical Medicine, 2019 , 29(004):362-366.

[13]Lei C J , Zhong H , Zhang H , et al. Clinical Efficacy of Multipoint Injection of Botulinum Toxin in the Treatment of Spastic Cerebral Palsy in Children[J].West China Medical Journal,2015, 13(006):73-76.

猜你喜欢

临床疗效
CRRT在重症胰腺炎中的应用及护理
核苷类药物治疗乙型肝炎肝硬化失代偿期的效果研究
黄葵胶囊联合缬沙坦治疗糖尿病肾病临床疗效
探讨氯吡格雷预防冠心病介入治疗心血管的临床疗效
131碘治疗甲亢患者的后期随访效果分析
枸橼酸咖啡因治疗早产儿原发性呼吸暂停临床分析
微创手术治疗胃溃疡42例临床分析
研究腹腔镜在早期卵巢癌分期手术中的临床应用
早期应用前列地尔治疗急性脑梗死临床疗效观察